The Journal of Neuroscience, May 16, 2007, 27(20):5394-5404; doi:10.1523/JNEUROSCI.5047-06.2007
Previous Article | Next Article 
Neurobiology of Disease
Connecting TNF-
Signaling Pathways to iNOS Expression in a Mouse Model of Alzheimer's Disease: Relevance for the Behavioral and Synaptic Deficits Induced by Amyloid ß Protein
Rodrigo Medeiros,1 *
Rui D. S. Prediger,1 *
Giselle F. Passos,1
Pablo Pandolfo,1
Filipe S. Duarte,1
Jeferson L. Franco,2
Alcir L. Dafre,2
Gabriella Di Giunta,3
Cláudia P. Figueiredo,3
Reinaldo N. Takahashi,1
Maria M. Campos,4 and
João B. Calixto1
Departamentos de 1Farmacologia and 2Ciências Fisiológicas, Centro de Ciências Biológicas, and 3Departamento de Anatomia Patológica, Hospital Universitário–Universidade Federal de Santa Catarina, 88049-900, Florianópolis, Santa Catarina, Brazil, and 4Faculdade de Odontologia, Pontifícia Universidade Católica do Rio Grande do Sul 90619-900, Rio Grande do Sul, Brazil
 |
Abstract
|
|---|
Increased brain deposition of amyloid ß protein (Aß) and cognitive deficits are classical signals of Alzheimer's disease (AD) that have been highly associated with inflammatory alterations. The present work was designed to determine the correlation between tumor necrosis factor-
(TNF-)-related signaling pathways and inducible nitric oxide synthase (iNOS) expression in a mouse model of AD, by means of both in vivo and in vitro approaches. The intracerebroventricular injection of Aß1–40 in mice resulted in marked deficits of learning and memory, according to assessment in the water maze paradigm. This cognition impairment seems to be related to synapse dysfunction and glial cell activation. The pharmacological blockage of either TNF- or iNOS reduced the cognitive deficit evoked by Aß1–40 in mice. Similar results were obtained in TNF- receptor 1 and iNOS knock-out mice. Aß1–40 administration induced an increase in TNF- expression and oxidative alterations in prefrontal cortex and hippocampus. Likewise, Aß1–40 led to activation of both JNK (c-Jun-NH2-terminal kinase)/c-Jun and nuclear factor-
B, resulting in iNOS upregulation in both brain structures. The anti-TNF- antibody reduced all of the molecular and biochemical alterations promoted by Aß1–40. These results provide new insights in mouse models of AD, revealing TNF- and iNOS as central mediators of Aß action. These pathways might be targeted for AD drug development.
Key words: Alzheimer's disease; amyloid ß; inflammation; TNF-; iNOS; cognitive deficits
|
Introduction
|
|---|
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with memory loss, spatial disorientation, and weakness of intellectual capacity. Histopathological studies of AD brain have revealed the presence of classical hallmarks including neurofibrillary tangles and senile plaques. The deposition of amyloid ß protein (Aß) in brain areas involved in cognitive functions is assumed to initiate a pathological cascade that results in synaptic dysfunction, synaptic loss, and neuronal death (Walsh and Selkoe, 2004
).
Recent evidence suggests an inflammatory component in AD, which is characterized by astrogliosis, microgliosis, cytokine elevation, and changes in acute phase proteins (Walsh and Selkoe, 2004; Wyss-Coray, 2006). Tumor necrosis factor- (TNF-) is a cytokine thought to play a central role in the self-propagation of neuroinflammation (Perry et al., 2001). TNF- regulates many cellular processes, including inflammation, differentiation, and cell death through activation of TNF receptor 1 (TNFR1) or TNFR2 (Wajant et al., 2003). The transduction pathways activated by TNF- include mitogen-activated protein kinases (MAPKs) and IB kinase, which control gene expression through transcriptional factors such as activator protein-1 (AP-1) and nuclear factor-B (NF-B) (Wajant et al., 2003). Regarding the CNS, microglia and astrocytes are believed to be the primary sources of TNF-. Evidence indicates the presence of increased levels of TNF- in the brain and plasma of AD patients and an upregulation of TNFR1 have been detected in the AD brain (Fillit et al., 1991; Li et al., 2004). In addition, TNF- has been implicated recently as a critical mediator of long-term potentiation (LTP) reduction by Aß (Wang et al., 2005). However, the mechanisms through which TNF- promotes its pathological actions in AD are poorly understood.
Brain oxidative stress seems to exert an important role in cognitive impairment observed in AD. Inducible nitric oxide synthase (iNOS) generates nitric oxide (NO) and NO-derived reactive nitrogen species such as peroxynitrite. Accumulation of highly reactive molecules induces lipid peroxidation, tyrosine nitrosylation, DNA oxidative damage, and neuronal disruption, which are common characteristics of the AD brain (Butterfield et al., 2001). Interestingly, these events seem to be modulated by TNF-. Also, Aß has been shown to interact in a synergistic manner with cytokines to induce neuronal damage via reactive oxygen species (ROS)- and NO-dependent pathways (Goodwin et al., 1995; Meda et al., 1995).
Numerous animal models have been used to evaluate the role of inflammation in the course of AD. An experimental model that mimics the progression of AD was developed using an intracerebroventricular injection of Aß in mice (for review, see Van Dam and De Deyn, 2006). Using this model, we assessed the role of TNF- and iNOS in Aß-induced early impairment of learning and memory. Our data indicate that TNF- production is one of the earliest events induced by Aß1–40, representing an important signal for iNOS expression. The cross talk between TNF- and iNOS is probably mediated by activation of two major intracellular pathways: c-Jun-NH2-terminal kinase (JNK)/c-Jun and NF-B. The present results implicate TNF- and iNOS as important mediators of Aß-induced cognitive impairment.
|
Materials and Methods
|
|---|
Subjects.
Experiments were conducted using male Swiss, C57BL/6, TNFR1 knock-out, and iNOS knock-out mice (20–30 g) kept in a controlled room temperature (22 ± 2°C) and humidity (60–80%) under a 12 h light/dark cycle (lights on 6:00 A.M.). TNFR1 (Rothe et al., 1993) and iNOS (MacMicking et al., 1995) knock-out mice are on the C57BL/6 background, constructed as described previously. All procedures used in the present study followed the "Principles of Laboratory Animal Care" from National Institutes of Health (NIH) publication number 85-23 and were approved by the Animal Ethics Committee of the Universidade Federal de Santa Catarina.
Drug treatment protocol.
Human Aß1–40 (Tocris, Ellisville, MO) and Aß40–1 (Bachem, Torrance, CA) were dissolved in sterile PBS, pH 7.4, at 1 mg/ml and were incubated at 37°C for 4 d, as described previously (El Khoury et al., 1996). Control mice received sterile PBS (vehicle). The aggregated form of amyloid fragments (400 pmol per mice) and vehicle solution were administered intracerebroventricularly as described previously (Laursen and Belknap, 1986). As a positive control for molecular studies, some animals received an intracerebroventricular injection of 2.5 µg of lipopolysaccharide (LPS) from Escherichia coli (serotype 0111:B4; Sigma-Aldrich, Sao Paulo, Brazil). Briefly, each mouse was given an injection at bregma with a 5 µl Hamilton microsyringe fitted with a 26 gauge needle that was inserted to a depth of 2.4 mm. The injection volume was 3 µl. Mice exhibited normal behavior within 1 min after injection. Accurate placement of the injection or needle track was verified at the time of dissection. The present Aß1–40 dose was selected according to previous literature data (Yan et al., 2001).
Some animals were treated with anti-TNF- antibody (AbTNF-; 10 
g, i.c.v., per mouse; R & D Systems, Minneapolis, MN) 15 min before Aß1–40 injection. The AbTNF- dose was determined in pilot experiments (results not shown). The iNOS inhibitor aminoguanidine (AG; 100 mg/kg, i.p.; Sigma-Aldrich) was administered 1 h before an intracerebroventricular injection of Aß1–40 and throughout consecutive days until the day of the experiment. In addition, some animals were pretreated with the selective inhibitor of JNK, SP600126 (anthra[1-9-cd]pyrazol-6(2H)-one; 50 mg/kg; i.p.; 1 h before; Tocris), or the NF-B blocker pyrrolidine dithiocarbamate (PDTC; 100 mg/kg, i.p., 1 h before; Sigma-Aldrich).
Water maze test–memory reference test.
The Morris water maze test was performed as described previously (Morris et al., 1982). The experimental apparatus consisted of a circular water tank (diameter, 97 cm; height, 60 cm) containing water at 23 ± 2°C. The target platform (10 x 10 cm) was submerged 1 cm below the water surface and placed at the midpoint of one quadrant. The platform was located in a fixed position, equidistant from the center and the wall of the pool. The pool was located in a test room containing various prominent visual cues. Mice were submitted to a spatial reference memory version of the water maze as described previously (Prediger et al., 2007). The acquisition training session was performed 7 d after Aß1–40 injection and consisted of 10 consecutive trials during which the animals were left in the tank facing the wall and allowed to swim freely to the escape platform. If an animal did not find the platform within a period of 60 s, it was gently guided to it. The animal was allowed to remain on the platform for 10 s after escaping to it, and it was then removed from the tank for 20 s before being placed at the next starting point in the tank. This procedure was repeated 10 times, with the starting points varying in a pseudo-randomized manner. The test session was performed 24 h after the training session (on day 8 after injection). The test session consisted of a single probe trial in which the platform was removed from the pool and each mouse was allowed to swim for 60 s in the maze. The time spent in the correct quadrant (i.e., where the platform was located on the training session) was recorded, and the percentage of the total time was calculated.
Open-field test.
To discard the possible effects on Aß1–40 in locomotor activity, the animals were tested in the open-field paradigm. The apparatus, made of wood covered with impermeable Formica, had a black floor of 30 x 30 cm (divided by white lines into nine squares of 10 x 10 cm) and transparent walls, 15 cm high. Each mouse was placed in the center of the open field, and the total number of squares crossed with the four paws and the rearing behavior were registered for 5 min.
Histology.
Eight days after intracerebroventricular injection of aggregated Aß1–40, mice were perfused transcardially with PBS solution containing 4% paraformaldeyde (w/v). Brain was removed and kept overnight in the same solution. Serial sections (3 µM) were selected to include the lateral ventricle areas. Sections were stained with 0.5% cresyl violet reagent (Sigma-Aldrich) according to standard procedures. Stained cells were determined on visual inspection in the hippocampal CA1, CA2, and CA3 subfields and cortical layer with a microscope (Eclipse 50I; Nikon, Melville, NY) using a counting grid at 400x magnification. The light-microscopic characteristics of the Aß1–40 aggregates were studied using the alkaline Congo red technique according to standard procedures.
Immunohistochemistry.
Immunohistochemistry detection of apoptotic cell death, immunoreactivity of the astrocyte marker glial fibrillary acidic protein (GFAP), and synaptic changes were assessed on paraffin tissue sections 1 and 8 d after Aß1–40 intracerebroventricular injection, using the polyclonal rabbit anti-caspase-3 (1:200; Cell Signaling Technology, Beverly, MA), monoclonal mouse anti-GFAP (1:300; Dako Cytomation, Carpinteria, CA), and monoclonal mouse anti-synaptophysin (1:400; Novocastra, Newcastle, UK), respectively. High-temperature antigen retrieval was performed by immersion of the slides in a water bath at 95–98°C in 10 mM trisodium citrate buffer, pH 6.0, for 45 min. The nonspecific binding was blocked by incubating sections for 1 h with goat normal serum diluted in PBS. After overnight incubation at 4°C with primary antibodies, the slides were washed with PBS and incubated with the secondary antibody Envision plus (Dako Cytomation), ready to use, for 1 h at room temperature. The sections were washed in PBS, and the visualization was completed by using 3,3'-diaminobenzidine (Dako Cytomation) in chromogen solution and counterstained lightly with Harris's hematoxylin solution. Images were taken with a microscope (Eclipse 50i; Nikon) and digital sight camera (DS-5M-L1; Nikon). Control and experimental tissues were placed on the same slide and processed under the same conditions. Settings for image acquisition were identical for control and experimental tissues. For each mouse, we obtained four images (one per section) of the parietal cortex and three images (one per section) of the hippocampal CA1, CA2, and CA3 subregions. Digitized, 8-bit images were transferred to a computer, and the average pixel intensity of synaptophysisn staining was calculated for each image using NIH ImageJ 1.36b imaging software (NIH, Bethesda, MD). For each mouse, the values obtained for the parietal cortex or the hippocampal subregions were averaged. This approach for the assessment of synaptic degeneration has been validated in various experimental models of neurodegeneration (Buttini et al., 1999) and in diseased human brains (Masliah et al., 1992). GFAP- and caspase-3-positive cells were determined on visual inspection in the same brain areas using a counting grid at 400x magnification.
Enzymatic studies.
Mice were anesthetized with pentobarbital (50 mg/kg, i.p.) and perfused transcardially with ice-cold 0.9% NaCl (10 ml/10 g body weight) to remove the free radical-scavenging and radical-generating sources in the brain. The prefrontal cortex and hippocampus were carefully excised and stored at –70°C. Tissues were homogenized in 20 mM HEPES, pH 7.0, and centrifuged at 20,000 x g for 30 min at 4°C. The enzyme activities were determined in the supernatant in a Varian (Palo Alto, CA) Cary 50 spectrophotometer. Glutathione reductase (GR) and glutathione peroxidase (GPx) activity was determined as described previously (Prediger et al., 2007). Briefly, GR reduces oxidized glutathione (GSSG) to glutathione (GSH) in expending NADPH, the disappearance of which can be accompanied at 340 nm. GPx activity was measured indirectly by the NADPH consumption at 340 nm. The GPx uses GSH to reduce the tert-butylhydroperoxide-producing GSSG, which is readily reduced to GSH by excess GR, consuming NADPH. The disappearance of NADPH in this reaction reflects the GPx activity. The enzyme activities were expressed in milliunits per milligram of total protein content, which was quantified using the Bio-Rad (Hercules, CA) protein assay kit.
Determination of total GSH level.
The prefrontal cortex and hippocampus were isolated and homogenized in cooled 0.5 M perchloric acid. The homogenates were centrifuged at 15,000 x g for 2 min, and the supernatant was separated, neutralized in potassium phosphate buffer (0.1 M, pH 7.4), and subsequently submitted to the assay. Total GSH, comprising the total of reduced (GSH) and oxidized (GSSG) forms, was determined by the GR–5',5'-dithio-bis(2-nitrobenzoic acid) recycling assay as described previously (Prediger et al., 2007).
Preparation of cytosolic and nuclear extracts.
Tissues were homogenized in ice-cold 10 mM HEPES, pH 7.4, containing 1.5 mM MgCl2, 10 mM KCl, 1 mM phenylmethylsulphonyl fluoride, 5 µg/ml leupeptin, 5 µg/ml pepstatin A, 10 µg/ml aprotinin, 1 mM sodium orthovanadate, 10 mM ß-glycerophosphate, 50 mM sodium fluoride, and 0.5 mM dithiothreitol (all from Sigma-Aldrich). The homogenates were chilled on ice for 15 min and vigorously shaken for 15 min in the presence of 0.1% Triton X-100. The nuclear fraction was precipitated by centrifugation at 10,000 x g for 30 min. The supernatant containing the cytosolic fraction was stored at –70°C until use. The nuclear pellet was resuspended in 500 µl of high-salt extraction buffer (20 mM HEPES, pH 7.4, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% v/v glycerol, 1 mM phenylmethylsulphonyl fluoride, 5 µg/ml pepstatin A, 5 µg/ml leupeptin, 10 µg/ml aprotinin, and 0.5 mM dithiothreitol) and incubated under continuous shaking at 4°C for 30 min. The nuclear extract was then centrifuged for 30 min at 10,000 x g, and the supernatant was aliquoted and stored at –70°C. Protein concentration was determined using the Bio-Rad protein assay kit.
Western blot analysis.
Equal protein amounts were separated on an SDS-PAGE and transferred to a polyvinylidene fluoride membrane (Immobilon P; Millipore, Bedford, MA). The membranes were saturated by incubation with 10% nonfat dry milk solution and incubated overnight with one of the following antibodies: p65 NF-B (sc-372, 1:1000), c-jun (sc-45, 1:1000), iNOS (sc-7271, 1:200), -actin (sc-1615, 1:2000), JNK1 (sc-571, 1:1000), phosphorylated JNK (sc-6254, 1:1000) (all from Santa Cruz Biotechnology, Santa Cruz, CA), or lamin A/C (catalog #2032; Cell Signaling Technology). After washing, the membranes were incubated with adjusted secondary antibodies coupled to horseradish peroxidase or alkaline phosphatase. The immunocomplexes were visualized using the ECL chemiluminescence detection system (GE Healthcare, Sao Paulo, Brazil) or 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium color development substrate (Promega, Madison, WI). Band density measurements were made using the Scion (Frederick, MD) Image software package.
RNA preparation and reverse transcription-PCR.
Total RNA was extracted from 
100 mg of prefrontal cortex and hippocampus using Trizol reagent (Invitrogen, Sao Paulo, Brazil) according to the manufacturer's instructions. The concentration of total RNA was determined by measuring the absorbance at 260 nm in a spectrophotometer. The quality of the preparations was checked using gel electrophoresis. One microgram of total RNA was reverse transcribed using oligo(dT) and 200 U of reverse transcriptase (Invitrogen) in 20 µl of PCR buffer containing (in mM) 0.5 dNTP, 10 DTT, 2.5 MgCl2, 50 KCl, and 20 Tris-HCl, pH 8.4. The samples were incubated for 5 min at 70°C, 5 min at 4°C, 1 h at 37°C, 5 min at 70°C, and 5 min at 4°C. Specific primers (Invitrogen) were used for TNF- (sense, TCTCATCAGTTCTATGGCCC; antisense, GGGAGTAGACAAGGTACAAC), iNOS (sense, CAGAAGCAGAATGTGACCATC; antisense, CTTCTGGTCGATGTCATGA), and ß-actin (sense, TCCTTCGTTGCCGGTCCACA; antisense, CGTCTCCGGAGTCCATCACA). ß-Actin cDNA was used for standardization of the amount of RNA. Five microliters of reverse transcription (RT) aliquots were mixed in a 20 mM Tris-HCl buffer, pH 8.4, containing 1.5 mM MgCl2, 300 µM dNTP, 2 µg/ml of each primer, and 50 U/ml Taq polymerase (Invitrogen) in a final volume of 100 µl. The following cycling protocol was used: initial denaturation, 95°C for 4 min; cycling: 95°C for 30 s, 53°C for 30 s (TNF- and iNOS) or 62°C for 30 s (ß-actin), and 72°C for 1 min; and a final extension period at 72°C for 5 min. Optimal amplification was achieved at 29 cycles for TNF-, iNOS, and ß-actin. Aliquots of 25 µl were analyzed by PAGE and stained with silver salts. Band density measurements for TNF-, iNOS, and ß-actin mRNAs were made using the Scion Image software package.
Software.
All Western blot and RT-PCR experiments were scanned to acquire digital images using a Genius ColorPage Scanner (KYE Systems, Taipei, Taiwan). Digital images were processed with the Photoshop software package (Adobe Systems, Mountain View, CA), complying with strict standards (Rossner and Yamada, 2004).
Statistical analysis.
All values are expressed as means ± SEM (n is the number of mice included in each analysis). Differences between groups in total GSH levels and GR and GPx activities were analyzed using an unpaired Student's t test. Statistical analysis for the rest of the data were performed using two- or three-way ANOVA with strain (or pretreatment), treatment, or the number of trials (repeated measure) as independent variables. After significant ANOVAs, multiple post hoc comparisons were performed using the Newman–Keuls test. The accepted level of significance for the tests was p < 0.05. All tests were performed using the Statistica software package (StatSoft, Tulsa, OK).
|
Results
|
|---|
The role of TNF- and iNOS in Aß-induced learning and memory impairment
Learning and memory functions are vulnerable to several pathological processes, including AD (Budson and Price, 2005). To investigate some of the mechanisms involved in Aß-induced cognitive decline, the Morris water maze task was used. We tested the ability of mice to acquire (training session) and retrieve (test session) spatial information as indicative of learning and memory functions. As expected, intracerebroventricular injection of Aß1–40 in Swiss mice resulted in a significant decline in both learning and memory, as indicated by longer latencies (Fig. 1A) and reduced target quadrant preference (Fig. 1B) during the probe trial. No cognitive deficits were observed in Swiss mice treated with the inverse Aß40–1 (Fig. 1). The effects of Aß1–40 administration on water maze performance are not directly related to motor impairment, because no alterations of the swimming speed in the water maze (data not shown), or the total squares crossed and rearing behavior in the open-field arena, were observed (Table 1).
View larger version (14K):
[in this window]
[in a new window]
|
Figure 1. Intracerebroventricular injection of Aß1–40 disrupts learning and memory in mice. The spatial reference memory version of the Morris water maze test in Swiss mice (n = 9–10 mice per group) was used as a measure of cognition. A, Training trials were performed on day 7 after a single intracerebroventricular administration of aggregated Aß1–40 (400 pmol per mouse), inverse peptide Aß40–1 (400 pmol per mouse) (used as a negative control), or vehicle (PBS). Treatment with Aß1–40 significantly increased the escape latencies to find the submerged platform during the training trials (F(2,26) = 104.32; p < 0.0001). B, The probe test session was performed 24 h after the training trials. Treatment with Aß1–40 reduced the frequency of time spent in the correct quadrant (F(2,26) = 19.91; p < 0.0001). The values represent the mean ± SEM. *p < 0.05 compared with the vehicle-treated group (Newman–Keuls test).
|
|
To verify whether TNF- and iNOS are required for Aß1–40-induced cognitive decline, pharmacological and genetic approaches were applied. Swiss mice were treated with the specific antibody against mouse TNF- (AbTNF-), 15 min before Aß1–40, or the preferential iNOS inhibitor AG, 1 h before Aß1–40, and throughout 7 consecutive days, until the test day (day 8 after injection). As shown in Figure 2, A and E, both pharmacological treatments resulted in a significant improvement of spatial learning deficits induced by Aß1–40, with a significant reduction in the final escape latency to find the platform in the training session. Additionally, the statistical analysis of the probe test scores revealed that either AbTNF- or AG significantly prevented the memory impairment induced by Aß1–40, increasing the time spent in the correct quadrant (Fig. 2B,F). Genetic deletion of TNFR1 or iNOS also significantly attenuated the spatial learning deficits induced by Aß1–40, as indicated by a reduction in the final escape latency to find the platform when compared with wild-type (C57BL/6) Aß-treated mice (Fig. 2C,G). In the test session, TNFR1–/– and iNOS–/– mice given injections of Aß1–40 presented higher swimming scores in the correct quadrant compared with wild-type Aß1–40-treated mice, indicating a diminished sensitivity to memory deficits (Fig. 2D,H).
View larger version (31K):
[in this window]
[in a new window]
|
Figure 2. Involvement of TNF- and iNOS in the cognitive deficits induced by Aß1–40 in mice. The spatial reference memory version of the Morris water maze test in mice was used as a measure of cognition. Training trials were performed on day 7 after a single intracerebroventricular administration of aggregated Aß1–40 (400 pmol per mouse) or vehicle (PBS). Data are presented as means ± SEM latency (seconds) for escape to a submerged platform (n = 8–10 mice per group). The probe test session was performed 24 h after training trials. Data are presented as means ± SEM of the frequency of time spent in the correct quadrant. A, B, E, F, Pretreatment with the specific antibody against mouse TNF- (AbTNF-; 10 g, i.c.v., per mouse) (A, B) or the preferential iNOS inhibitor AG (100 mg/kg, i.p., once per day) (E, F) improved the cognitive deficits induced by Aß1–40 in Swiss mice during training trials (AbTNF-: F(1,27) = 21.89, p < 0.0001; AG: F(1,33) = 82.78, p < 0.0001) and test sessions (AbTNF-: F(1,27) = 5.26, p < 0.05; AG: F(1,33) = 29.14, p < 0.0001) of the Morris water maze. C, D, G, H, TNFR1 knock-out (TNFR1–/–; C, D) and iNOS knock-out (iNOS–/–; G, H) mice were significantly more resistant than wild-type C57BL/6 mice to the deleterious effect of Aß1–40 in the spatial learning (TNFR1–/–: F(1,30) = 29.58, p < 0.0001; iNOS–/–: F(1,26) = 81.46, p < 0.0001) and spatial retrieval (TNFR1–/–: F(1,30) = 15.45, p < 0.001; iNOS–/–: F(1,26) = 28.46, p < 0.0001). *p < 0.05 compared with the vehicle/PBS-treated group; #p < 0.05 compared with the Aß1–40/PBS-treated group (Newman–Keuls test).
|
|
Prevention of synaptic dysfunction by TNF- and iNOS inhibition
To evaluate the possible amyloid deposits and/or neuronal damage after Aß1–40 intracerebroventricular injection, we performed histological and immunohistochemistry analysis. Histological examination was performed on cresyl violet- and on Congo red-stained sections of mouse brain, 8 d after the intracerebroventricular administrations. Cresyl violet-stained sections indicated that injection by itself failed to produce any significant neuronal damage in control animals, at or distant from the injection site. The administration of Aß1–40 peptide also failed to produce any neuronal loss in the hippocampus or cortex of treated mice (data not shown). Using Congo red staining, control brain sections or brain sections of animals treated with Aß1–40 showed no evidence of amyloid deposits (data not shown).
To further evaluate the neuronal integrity, we performed immunohistochemistry analysis for the presynaptic protein synaptophysin and the pro-apoptotic protein caspase-3 in the parietal cortex and the hippocampal CA1, CA2, and CA3 subregions 1 and 8 d after Aß1–40 intracerebroventricular injection. No modification in the synaptophysin levels was found 1 d after Aß1–40 treatment (results not shown). However, a significant reduction in the synaptophysin levels was found in Aß1–40-treated mice 8 d after intracerebroventricular injection, suggesting a decrease in synaptic density (Fig. 3 and supplemental Fig. 1, available at www.jneurosci.org as supplemental material). On the other hand, no alteration was observed for caspase-3 protein immunostaining at day 1 or 8, indicating that neuronal apoptosis was not activated, at least not up to 8 d after Aß1–40 treatment (data not shown). Also, either AbTNF- or AG (Fig. 3A–D) significantly prevented Aß1–40-induced decrease in synaptophysin levels 8 d after Aß1–40 treatment. Consistent with these findings, comparable results were seen in TNFR1–/– and iNOS–/– (Fig. 3A–D) mice. Extending previous data (Walsh and Selkoe, 2004), our results indicated that synaptic dysfunction precedes neuronal death in the AD brain through a mechanism that is dependent on TNF- and iNOS.
View larger version (30K):
[in this window]
[in a new window]
|
Figure 3. TNF- and iNOS participate in Aß1–40-induced synaptic disruption. Immunohistochemistry analysis for the presynaptic protein synaptophysin was performed on day 8 after aggregated Aß1–40 (400 pmol per mouse) intracerebroventricular injection. A–H, Relative optical densitometry of synaptophysin immunostaining in the CA1 (A, B), CA2 (C, D), and CA3 (E, F) subregions of the hippocampus and parietal cortex (G, H). Synaptophysin immunoreactivity was used as a measure of synaptic density. A, C, E, G, Pretreatment with the specific antibody against mouse TNF- (AbTNF-; 10 g, i.c.v., per mouse) or with the preferential iNOS inhibitor AG (100 mg/kg, i.p., once per day) prevented the Aß1–40-induced synaptic disruption in Swiss mice in the CA1 (F(3,8) = 9.38; p < 0.01; A) and CA2 (F(3,8) = 9.44; p < 0.01; C), but not in the CA3 (F(3,8) = 4.02; p < 0.05; E) and parietal cortex (F(3,8) = 3.26; p = 0.08; G). B, D, F, H, TNFR1 knock-out (TNFR1–/–) and iNOS knock-out (iNOS–/–) mice were significantly more resistant than wild-type C57BL/6 mice to the Aß1–40-induced synaptic disruption in the CA2 (F(3,8) = 4.79; p < 0.05; D) and CA3 (F(3,8) = 4.63; p < 0.05; F), but not in the CA1 (F(3,8) = 3.17; p = 0.08; B) and parietal cortex (F(3,8) = 4.00; p < 0.05; H). The values represent the mean ± SEM. *p < 0.05, **p < 0.01 compared with the control group (naive); #p < 0.05, ##p < 0.01 compared with the Aß1–40/PBS-treated group (Newman–Keuls test).
|
|
Aß-induced astrocyte activation
Astrogliosis is one of the earliest pathological hallmarks of AD and may occur in response to the increasing number of degenerating neurons and synapses, or to the accumulation of Aß. The injection of Aß1–40 induced an increase in the astrocyte activation at day 1 after Aß1–40 intracerebroventricular injection, mainly in the hippocampus, as demonstrated by a rise in the number of GFAP-positive cells (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). No significant alteration in the GFAP immunoreactivity was found in the parietal cortex, whereas the GFAP detection was reduced 8 d after Aß1–40 treatment in the hippocampus (data not shown). The involvement of TNF- and iNOS for the activation of astrocytes was also verified. Results show that treatment with AbTNF- or AG failed to reduce the immunoreactivity to GFAP in Aß-injected mice 1 d after treatment (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). These data were also confirmed by experiments using knock-out mice. TNFR1–/– or iNOS–/– mice failed to prevent GFAP immunodetection compared with wild-type (C57BL/6) Aß-treated mice (supplemental Fig. 2, available at www.jneurosci.org as supplemental material). These data indicate that astrogliosis present a role in the initial inflammatory response induced by Aß1–40 in the AD model. In addition, it suggests that astrocyte activation may be involved in initial TNF- release. However, additional studies are necessary to confirm this hypothesis.
Aß stimulates iNOS protein expression through TNF- production
Next, we attempted to outline the temporal sequence of intracellular events after Aß1–40 intracerebroventricular injection. The expression of TNF- and iNOS was assessed in the hippocampus and prefrontal cortex at different time points after Aß1–40 injection using RT-PCR and/or Western blot techniques. Under basal conditions, very low levels of TNF- mRNA were observed in the hippocampus or prefrontal cortex. Conversely, a rapid onset and time-dependent induction of TNF- mRNA was observed in Aß1–40-treated mice (Fig. 4A,B). The increase in TNF- mRNA levels was detected after 15 min of Aß1–40 treatment, remaining elevated through 24 h, and it was found to be diminished after 7 d in both brain structures. Similarly, the time-course analysis revealed that iNOS mRNA expression was minimal under basal conditions but increased in a time-dependent manner, peaking at 1–3 h and being reduced 24 h after Aß1–40 treatment (Fig. 4A,B). Moreover, Western blot analysis indicated that Aß1–40 intracerebroventricular injection led to a sustained iNOS protein expression in both brain regions. As seen in Figure 4, C and D, little alteration of iNOS expression was verified up to 60 min, but a marked increase was demonstrated at 3 h, remaining elevated for at least 7 d. These time-related changes might indicate a correlation between TNF- mRNA induction and iNOS mRNA/protein expression (Fig. 4E,F). Thus, we examined the effects of TNF- signaling blockage on Aß1–40-induced iNOS expression. The treatment with AbTNF- almost completely inhibited iNOS protein expression, without affecting the control protein -actin (Fig. 4C,D). Last, as a control for the Aß1–40, we treated mice with the reverse peptide Aß40–1 and found that it had no significant effect on the TNF- mRNA (results not shown) or iNOS expression (Fig. 4C,D). In our model, TNF- production appears to be one of the earliest events induced by Aß, representing a signal for iNOS protein expression.
View larger version (62K):
[in this window]
[in a new window]
|
Figure 4. Requirement of TNF- for Aß1–40-induced iNOS upregulation. Swiss mice were treated with aggregated Aß1–40 (400 pmol, i.c.v., per mouse) [except naive, untreated mice (N)], and the hippocampus and prefrontal cortex were isolated at the time points indicated. A, B, Total RNA was isolated from the hippocampus (A) and prefrontal cortex (B) for evaluation of TNF- and iNOS expression by RT-PCR. ß-Actin mRNA was assessed in all RNA samples as an internal control for the amount of RNA in each sample. TNF- and iNOS mRNA increased in a time-dependent manner after Aß1–40 intracerebroventricular treatment, whereas ß-actin levels remained constant. C, D, Aß1–40 induced a time-dependent and prolonged iNOS protein expression in the hippocampus (C) and prefrontal cortex (D). Western blot analysis revealed that pretreatment with the specific antibody against mouse TNF- (AbTNF-; 10 g, i.c.v., per mouse) prevented Aß1–40-induced iNOS expression in the hippocampus (F(1,36) = 118.26; p < 0.0001) and prefrontal cortex (F(1,36) = 87.69; p < 0.0001). Immunoblot for -actin was used as a cytosolic loading control. Treatment with the reverse peptide Aß40–1 (6 h) had no effect on the iNOS protein expression. As a positive control, LPS (2.5 µg, i.c.v., 12 h) treatment induced a marked iNOS protein expression. E, F, Graph illustrating the temporal profile of the TNF- and iNOS mRNA synthesis and iNOS protein expression in the hippocampus (E) and prefrontal cortex (F). Results were normalized by arbitrarily setting the densitometry from the maximal responsive group and are expressed as the mean of three to four independent experiments.
|
|
Oxidative stress induced by Aß depends on TNF-
Previous evidence suggests a causal linkage among Aß, iNOS expression, and cellular redox state. NO generated by iNOS reacts with superoxide anion (O
) producing peroxynitrite (ONOO–) that exerts cytotoxic effects (Beckman et al., 1990). Thus, it is reasonable to expect that Aß1–40-induced iNOS expression is accompanied by oxidative alterations, in a TNF--dependent process. Although quantification of NO is more related with our data, it is well accepted that GSH parameters are associated with cellular oxidative state, and this might be indirectly modified by augmentation in the NO production. Hence, we evaluated the GSH status and GSH-dependent enzyme activities after Aß1–40 treatment. As shown in supplemental Figure 3 (available at www.jneurosci.org as supplemental material), total GSH levels were reduced on days 1 and 7 after intracerebroventricular injection in the hippocampus and prefrontal cortex of Aß1–40-treated Swiss mice, respectively. In addition, GR and GPx activities were significantly increased by Aß1–40 in both brain structures on day 1 after injection, returning to basal values after 7 d (supplemental Fig. 3, available at www.jneurosci.org as supplemental material). As expected, AbTNF- treatment reverted all the oxidative alterations induced by Aß1–40 in the hippocampus and prefrontal cortex (Fig. 5). These results establish TNF- as a critical modulator of the oxidative responses induced by Aß.
View larger version (27K):
[in this window]
[in a new window]
|
Figure 5. Blockade of TNF- prevents alterations in GSH-dependent antioxidant parameters induced by Aß1–40. Swiss mice were treated with a specific antibody against mouse TNF- (AbTNF-; 10 g, i.c.v., per mouse) 15 min before the administration of the aggregated Aß1–40 (400 pmol per mouse) or vehicle (PBS). A–F, Total GSH levels (GSH total; A, B) and antioxidant enzymes, GR (C, D), and GPx (E, F) were measured in the hippocampus and prefrontal cortex of Swiss mice at 24 h after Aß1–40 administration. The values represent the mean ± SEM of GSH total levels (micromoles per gram of wet tissue) and GR and GPx activities (milliunits per milligram of protein) (n = 5–7 mice per group). A, B, Treatment with AbTNF- prevented the reduction in GSH total levels in the hippocampus (F(3,16) = 18.04; p < 0.0001; A) and prefrontal cortex (B) of Aß1–40-treated mice. C–F, AbTNF- treatment prevented the increase in GR and GPx activities in the hippocampus (C, E) (F(3,16) = 2.05, p < 0.05 and F(3,16) = 5.13, p < 0.001, respectively) and (D, F) prefrontal cortex (F(3,16) = 5.68, p < 0.01 and F(3,16) = 4.17, p < 0.05, respectively) induced by Aß1–40 injection. The values represent the mean ± SEM. *p < 0.05 compared with the vehicle/PBS-treated group; #p < 0.05 compared with the Aß1–40/PBS-treated group (Newman–Keuls test).
|
|
JNK/c-Jun pathway involvement in Aß-induced iNOS expression
Recent evidence suggests that JNK and its target c-Jun play an important role in AD neural dysfunction (Bozyczko-Coyne et al., 2001; Morishima et al., 2001; Troy et al., 2001). We next tested the possible requirement of JNK and c-Jun for Aß-mediated effects in our AD paradigm. As shown in Figure 6, A and B, a low basal level of activated JNK was detected in the hippocampus and prefrontal cortex. However, an evident increase in JNK phosphorylation was found between 15 and 30 min. This reached a peak at 6 h and lasted for up to 7 d after Aß1–40 treatment in both brain regions. The increase in JNK activation was accompanied by a rise in c-Jun translocation to the nucleus (Fig. 6C,D), which suggests a possible association between these events. To confirm this, mice were treated with the JNK inhibitor SP600125 (1 h before Aß1–40), and the hippocampus and prefrontal cortex were isolated for Western blot analysis. As expected, nuclear c-Jun (Fig. 6E,F) was found to be reduced in both brain structures of SP600125-treated mice.
View larger version (69K):
[in this window]
[in a new window]
|
Figure 6. Aß1–40-induced JNK/c-Jun pathway activation. A, B, Activation of cytoplasmic JNK in response to aggregate Aß1–40 intracerebroventricular injection was detected in the hippocampus (A) and prefrontal cortex (B) of Swiss mice, at the time points indicated, by phosphospecific antibody for diphosphorylated JNK (p-JNK; at Thr183 and Tyr185). Blots were reprobed with anti-JNK to verify equal loading. C, D, Kinetics of c-Jun protein translocation from cytoplasm into the nucleus in the hippocampus (C) and prefrontal cortex (D) after Aß1–40 administration. Activation of the JNK pathway is dependent on TNF-. Pretreatment with the specific antibody against mouse TNF- (AbTNF-; 10 g, i.c.v., per mouse) prevented Aß1–40-induced JNK activation and subsequent c-Jun translocation in the hippocampus and prefrontal cortex. Immunoblot for lamin A/C was used as a nuclear loading control. N, Naïve, untreated mice. Treatment with the reverse peptide Aß40–1 (6 h) had no significant effect on the JNK/c-Jun activation. As a positive control, LPS (2.5 µg, i.c.v., 1 h) treatment induced activation in the JNK/c-Jun pathway. E, F, Pretreatment with JNK inhibitor SP600125 (25 mg/kg, i.p., 1 h before Aß), but not with NF-B inhibitor PDTC (100 mg/kg, i.p., 1 h before Aß), prevented Aß1–40-induced c-Jun translocation in the hippocampal (E) and cortical (F) homogenates. Brain samples were collected 6 h after Aß1–40 intracerebroventricular injection. These data indicate an association between JNK and c-Jun proteins.(C), Cytoplasmatic; (N), nuclear.
|
|
TNF- signaling effectors include JNK and c-Jun that might also contribute to iNOS promoter activity (Eberhardt et al., 1996). Pretreatment with AbTNF- completely blocked Aß1–40-caused JNK phosphorylation (Fig. 6A,B) and c-Jun nuclear translocation (Fig. 6C,D) in the hippocampus and prefrontal cortex. Moreover, the Western blot analysis applied to brain samples of SP600125-treated mice revealed a partial reduction in the iNOS expression (see Fig. 8). These data indicate a sequence of events subsequent to Aß1–40 intracerebroventricular injection that involves TNF- production, JNK phosphorylation, c-Jun translocation, and iNOS expression.
TNF- regulates Aß-induced iNOS expression via NF-B activation
In resting cells, NF-B dimmers are found in the cytoplasm associated with IB proteins. Pathological conditions (including AD) result in NF-B translocation to the nucleus where it regulates the transcription of several genes (Ghosh and Karin, 2002). To analyze the possible involvement of NF-B in Aß1–40-induced iNOS expression, we first assessed the temporal profile of NF-B activation after Aß1–40 treatment. Immunodetection of p65 subunit performed in the cytosolic and nuclear homogenates from hippocampus and prefrontal cortex confirmed the activation of NF-B. As shown in Figure 7, A and B, p65 was found to be increased in nuclear extracts after 15 and 30 min of Aß1–40 treatment, respectively. After 7 d, nuclear p65 levels returned toward baseline in both brain areas. Next, we determined to what extent NF-B activation caused by Aß1–40 was dependent on the TNF-. The AbTNF- almost completely blocked the translocation of NF-B induced by Aß1–40 (Fig. 7A,B). To further verify how NF-B activation could participate in the iNOS expression induced by Aß1–40, Swiss mice were treated with the NF-B inhibitor PDTC, at a dose that was sufficiently effective to prevent p65 translocation to the nucleus (Fig. 7C,D). PDTC was given intraperitoneally 60 min before Aß1–40 injection, and the hippocampus and the prefrontal cortex were isolated 24 h later for Western blot analysis. Data in Figure 8, A and B, show that PDTC-treated mice presented a significant reduction in Aß-induced iNOS expression in both brain regions. Collectively, these results suggest that Aß1–40-induced iNOS expression is dependent, at least in part, on TNF--driven NF-B activation.
View larger version (89K):
[in this window]
[in a new window]
|
Figure 7. Aß1–40-induced NF-B pathway activation. A, B, Cytoplasmic [(C)] and nuclear [(N)] samples of hippocampus (A) and prefrontal cortex (B) from Swiss mice were probed with a p65 NF-B antibody at the time points indicated. Data indicate that Aß1–40 induced a translocation of p65 NF-B from the cytoplasm to the nucleus. Pretreatment with the specific antibody against mouse TNF- (AbTNF-; 10 g, i.c.v., per mouse) prevented Aß1–40 induction of p65 NF-B translocation in hippocampus and prefrontal cortex. Immunoblot for lamin A/C was used as a nuclear loading control. Treatment with the reverse peptide Aß40–1 (6 h) had no significant effect on the p65 NF-B translocation. As a positive control, LPS (2.5 µg, i.c.v., 1 h) treatment resulted in p65 NF-B migration into the nucleus. C, D, Aß1–40-induced p65 NF-B translocation was prevented by pretreatment with NF-B inhibitor PDTC (100 mg/kg, i.p.), but not by pretreatment with JNK inhibitor SP600125 (25 mg/kg, i.p.), in hippocampus (C) and prefrontal cortex (D). These data indicate that JNK/c-Jun and NF-B pathways are independently activated by Aß1–40 intracerebroventricular injection. N, Naïve, untreated mice; C, control.
|
|
|
Discussion
|
|---|
Evidence suggests that inflammatory reaction induced by Aß in the CNS involves the release of damaging factors, such as cytokines, NO, and ROS, that promote the activation of intracellular pathways, contributing to the progression of AD (Walsh and Selkoe, 2004; Wyss-Coray, 2006). In the present study, we demonstrate that a single intracerebroventricular injection of Aß1–40, at a picomolar dose, induces a neuroinflammatory response that is linked to a decline in learning and memory functions. Present results are suggestive of glial activation and synaptic loss after Aß1–40 injection; however, assessment of apoptotic protein caspase-3 and cresyl violet staining indicated that programmed cell death seems not likely involved. Of high interest, the cognitive decline found after Aß1–40 treatment appears to be related to the synaptic loss. This supports the idea that synaptic dysfunction induced by Aß is the primary marker of AD and precedes neuronal death (Walsh and Selkoe, 2004). In addition, by use of pharmacological and molecular tools, we have shown a connecting link between Aß, TNF-, iNOS, oxidative stress, and the cognitive decline. Our results suggest that TNF-, probably through TNFR1 activation, exerts an essential role in Aß-mediated iNOS expression and oxidative alterations, culminating in synaptic failure and, consequently, in cognitive impairment observed in the current AD model.
TNF- is a multifunctional cytokine that triggers a wide range of cellular responses. In the CNS, TNF- (through activation of TNFR1) disrupts learning and memory and regulates neuronal death. TNF- has also been shown to participate in Aß-induced inhibition of LTP, a form of synaptic plasticity closely associated with learning and memory, and it is probably dependent on mGluR5 (metabotropic glutamate receptor 5) and p38 MAPK (Wang et al., 2005). Moreover, the activation of programmed cell death seems to rely on the TNF- signaling pathway. TNFR1 contains a cytoplasmatic death domain (DD) that binds to adaptor TRADD (TNFR-associated DD), which indirectly activates caspase cascades, causing apoptosis (Varfolomeev and Ashkenazi, 2004). In this context, it has been suggested that Aß1–40 binds directly to TNFR1, resulting in neuronal apoptosis (Li et al., 2004). Our data clearly demonstrate that Aß1–40 induced the expression of TNF- in the hippocampus and prefrontal cortex, two brain areas essential for the cognitive functions. Despite mRNA, TNF- levels started to reduce before 6 h; it is reasonable to expect that TNF- protein remains elevated for a longer period. In fact, Song et al. (2001) have shown that Aß1–42 intracerebroventricular injection in mice results in a rapid onset and time-dependent TNF- protein expression, which is maximal at 4 h, returning to basal values only after 72 h. A similar effect might be expected in our experimental paradigm. Notably, pharmacological and genetic inhibition of TNF- signaling reduced the synaptic loss and improved the learning and memory performance in Aß-treated mice even 8 d after treatment. These findings clearly place TNF- as one of the earliest mediators in the neurodegenerative process induced by Aß1–40. However, additional studies are necessary to determine whether or not TNF- effects depend on the participation of other inflammatory proteins (e.g., IL-1ß, IL-6, MCP-1).
The signal transduction cascades elicited by TNF- culminate in the activation of key transcriptional regulators, including NF-B (Beg et al., 1993) and AP-1 (Angel and Karin, 1991). In most cell types, NF-B complexes are found in the cytoplasm associated with IBs, which prevent their nuclear localization. Cell stimulation and/or injury leads to the rapid degradation of IB, allowing NF-B translocation to the nucleus, where it regulates the transcription of several genes (Ghosh and Karin, 2002). Functional NF-B dimers are present in essentially all cell types in the CNS, including neurons, astrocytes, microglia, and oligodendrocytes (O'Neill and Kaltschmidt, 1997). In AD brains, NF-B immunoreactivity is greater in neurons and astrocytes surrounding amyloid plaques (Terai et al., 1996; Kaltschmidt et al., 1997). Additionally, it has been reported that Aß stimulation leads to NF-B activation in cultured neurons and glia (Akama et al., 1998). Corroborating these findings, we demonstrate that Aß promotes NF-B activation in the hippocampus and prefrontal cortex through a TNF- dependent pathway.
AP-1 is a transcriptional factor composed of the protein products of c-jun and c-fos, and their expression is stimulated by cytokines (Angel and Karin, 1991). Phosphorylation and activation of c-Jun is catalyzed by the MAPK family members JNKs. The activation of both JNK and c-Jun has been described in cultured neurons after Aß exposure, and their inhibition attenuates Aß toxicity (Bozyczko-Coyne et al., 2001; Morishima et al., 2001; Troy et al., 2001). JNK activation has also been implicated in Aß-mediated LTP decline, indicating a possible role for learning and memory (Wang et al., 2004a). In the present study, we demonstrate that Aß1–40 produced a rapid and sustained activation of JNK and its target c-Jun, via mechanisms possibly dependent on TNF-. These results are consistent with previous reports indicating that JNK pathways are activated in the AD brain (Anderson et al., 1996; Zhu et al., 2001).
In the CNS, iNOS is not commonly found in healthy tissues, but it can be expressed after brain insult in astrocytes, neurons, and endothelial cells, where it triggers the production of high amounts of NO (Vallance and Leiper, 2002). Overproduction of NO may lead to neuronal damage and death. The predominant mechanism by which NO promotes neuronal toxicity implicates the reaction of NO with superoxide anion to generate the cytotoxic substance peroxynitrite (Beckman et al., 1990; Vallance and Leiper, 2002). Under physiological conditions, highly reactive molecules are rapidly eliminated by antioxidant enzymes, including GPxs (Thannickal and Fanburg, 2000). However, in pathological conditions, excessively accumulated reactive species induce several cellular dysfunctions (Thannickal and Fanburg, 2000). The present data revealed that intracerebroventricular Aß1–40 injection induced a marked iNOS expression, a phenomenon accompanied by a reduction in GSH levels, suggesting a possible increase in the production of reactive species, including NO. The iNOS inhibition or the iNOS genetic deletion significantly protected mice from Aß1–40-induced impairment of learning and memory. These protective effects might be explained by a reduction in synaptic disruption. The expression of iNOS and the NO synthesis have been deeply associated with AD pathology. In this context, it has been demonstrated that both iNOS expression and peroxynitrite damage take place in the AD brain (Smith et al., 1997; Luth et al., 2002). A recent report showed that genetic deletion of iNOS substantially protected mice from Aß toxicity (Nathan et al., 2005). Furthermore, it has been demonstrated that iNOS exerts an important role in Aß-caused cognitive deficits in rats and mice (Tran et al., 2001; Wang et al., 2004b).
Production of iNOS protein is tightly regulated at the transcriptional level, but the upstream signaling events mediating Aß-induced iNOS expression remain poorly understood. For instance, the molecular cloning and analysis of the promoter region of iNOS gene revealed the presence of binding sites to several transcriptional factors, such as AP-1, NF-B, and TNF response element (Eberhardt et al., 1996). Of high interest, in the present study, we show for the first time that iNOS induction by Aß1–40 depends on the TNF- signaling, with involvement of JNK/c-Jun and NF-B (for more details, see the proposed scheme in supplemental Fig. 4, available at www.jneurosci.org as supplemental material). These results also extend the notion that iNOS protein represents an unusual enzyme that can be modulated by highly specialized mechanisms.
Overall, our study suggests that TNF- and iNOS signaling pathways are linked and exert an important role in the cognitive deficits observed in the earlier stages of AD. Additional characterization of a candidate substrate(s) for both proteins would help to clarify their role and potential as molecular targets for therapeutic intervention in human AD.
|
Footnotes
|
|---|
Received Nov. 21, 2006;
revised April 14, 2007;
accepted April 17, 2007.
*R.M. and R.D.S.P. contributed equally to this work. 
This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico, the Coordenacão de Aperfeiçoamento de Pessoal de Nível Superior, the Programa de Apoio aos Núcleos de Excelência, and the Fundação de Apoio a Pesquisa do Estado de Santa Catarina, all from Brazil.
Correspondence should be addressed to Dr. João B. Calixto, Departamento de Farmacologia, Universidade Federal de Santa Catarina, Campus Universitário, Trindade, Bloco D, Caixa Postal 476, 88049-900, Florianópolis, Santa Catarina, Brazil. Email: calixto{at}farmaco.ufsc.br or Email: calixto3{at}terra.com.br
Copyright © 2007 Society for Neuroscience 0270-6474/07/275394-11$15.00/0
|
References
|
|---|
Anderson AJ, Su JH, Cotman CW (1996) DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 16:1710–1719.[Abstract/Free Full Text]
Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129–157.[Medline]
Akama KT, Albanese C, Pestell RG, Van Eldik LJ (1998) Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci USA 95:5795–5800.[Abstract/Free Full Text]
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620–1624.[Abstract/Free Full Text]
Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr (1993) Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of Ikappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol 13:3301–3310.[Abstract/Free Full Text]
Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW (2001) CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 77:849–863.[CrossRef][Web of Science][Medline]
Budson AE, Price BH (2005) Memory dysfunction. N Engl JMed 352:692–699.[Free Full Text]
Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7:548–554.[CrossRef][Web of Science][Medline]
Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW (1999) Expression of human apolipoprotein E3 or E4 in the brains of Apoe–/– mice: isoform-specific effects on neurodegeneration. J Neurosci 19:4867–4880.[Abstract/Free Full Text]
Eberhardt W, Kunz D, Hummel R, Pfeilschifter J (1996) Molecular cloning of the rat inducible nitric oxide synthase gene promoter. Biochem Biophys Res Commun 223:752–756.[CrossRef][Web of Science][Medline]
El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382:716–719.[CrossRef][Medline]
Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G (1991) Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 129:318–320.[CrossRef][Web of Science][Medline]
Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109:S81–S96.[CrossRef][Web of Science][Medline]
Goodwin JL, Uemura E, Cunnick JE (1995) Microglial release of nitric oxide by the synergistic action of ß-amyloid and IFN-
. Brain Res 692:207–214.[CrossRef][Web of Science][Medline]
Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C (1997) Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 94:2642–2647.[Abstract/Free Full Text]
Laursen SE, Belknap JK (1986) Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16:355–357.[CrossRef][Web of Science][Medline]
Li R, Yang L, Lindholm K, Konishi Y, Yue X, Hampel H, Zhang D, Shen Y (2004) Tumor necrosis factor death receptor signaling cascade is required for amyloid-ß protein-induced neuron death. J Neurosci 24:1760–1771.[Abstract/Free Full Text]
Luth HJ, Munch G, Arendt T (2002) Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 953:135–143.[CrossRef][Web of Science][Medline]
MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N, Chen H, Mudget JS (1995) Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641–650.[CrossRef][Web of Science][Medline]
Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA (1992) Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 32:321–329.[CrossRef][Web of Science][Medline]
Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D, Rossi F (1995) Activation of microglial cells by ß-amyloid protein and interferon-. Nature 374:647–650.[CrossRef][Medline]
Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME (2001) ß-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21:7551–7560.[Abstract/Free Full Text]
Morris RGM, Garrud P, Rawlins JNP, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681–683.[CrossRef][Medline]
Nathan C, Calingasan N, Nezezon J, Ding A, Lucia MS, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NS, Chen J, Vodovotz Y, Kipiani K, Beal MF (2005) Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med 202:1163–1169.[Abstract/Free Full Text]
O'Neill LA, Kaltschmidt C (1997) NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 20:252–258.[CrossRef][Web of Science][Medline]
Perry RT, Collins JS, Wiener H, Acton R, Go RC (2001) The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 22:873–883.[CrossRef][Web of Science][Medline]
Prediger RD, Franco JL, Pandolfo P, Medeiros R, Duarte FS, Di Giunta G, Figueiredo CP, Farina M, Calixto JB, Takahashi RN, Dafre AL (2007) Differential susceptibility following beta-amyloid peptide-(1–40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav Brain Res 177:205–213.[CrossRef][Web of Science][Medline]
Rossner M, Yamada KM (2004) What's in a picture? The temptation of image manipulation. J Cell Biol 166:11–15.[Free Full Text]
Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H (1993) Mice lacking the tumor necrosis factor receptor 1 are resistant but highly susceptible to infection by Listeria monocytogenes. Nature 364:798.[CrossRef][Medline]
Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17:2653–2657.[Abstract/Free Full Text]
Song DK, Im YB, Jung JS, Cho J, Suh HW, Kim YH (2001) Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice. J Neurochem 76:1326–1335.[CrossRef][Web of Science][Medline]
Terai K, Matsuo A, McGeer PL (1996) Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 735:159–168.[CrossRef][Web of Science][Medline]
Thannickal VJ, Fanburg BL (2000) Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279:L1005–L1028.[Abstract/Free Full Text]
Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, Nabeshima T (2001) Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 15:1407–1409.[Abstract/Free Full Text]
Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA (2001) Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 77:157–164.[Web of Science][Medline]
Vallance P, Leiper J (2002) Blocking NO synthesis: how, where and why? Nat Rev Drug Discov 1:939–950.[CrossRef][Web of Science][Medline]
Van Dam D, De Deyn PP (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5:956–970.[CrossRef][Web of Science][Medline]
Varfolomeev EE, Ashkenazi A (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116:491–497.[CrossRef][Web of Science][Medline]
Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65.[CrossRef][Web of Science][Medline]
Walsh DM, Selkoe DJ (2004) Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181–193.[CrossRef][Web of Science][Medline]
Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004a) Block of long-term potentiation by naturally secreted and synthetic amyloid ß-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370–3378.[Abstract/Free Full Text]
Wang Q, Rowan MJ, Anwyl R (2004b) ß-Amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24:6049–6056.[Abstract/Free Full Text]
Wang Q, Wu J, Rowan MJ, Anwyl R (2005) Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22:2827–2832.[CrossRef][Web of Science][Medline]
Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005–1015.[CrossRef][Web of Science][Medline]
Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, Huh SO, Suh HW, Kim YH, Song DK (2001) Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133:89–96.[CrossRef][Web of Science][Medline]
Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, Smith MA (2001) Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 76:435–441.[CrossRef][Web of Science][Medline]
This article has been cited by other articles:
|
|
|
|
 
P. Lu, T. Mamiya, L. L. Lu, A. Mouri, M. Niwa, M. Hiramatsu, L. B. Zou, T. Nagai, T. Ikejima, and T. Nabeshima
Silibinin Attenuates Amyloid {beta}25-35 Peptide-Induced Memory Impairments: Implication of Inducible Nitric-Oxide Synthase and Tumor Necrosis Factor-{alpha} in Mice
J. Pharmacol. Exp. Ther.,
October 1, 2009;
331(1):
319 - 326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Passos, C. P. Figueiredo, R. D. S. Prediger, P. Pandolfo, F. S. Duarte, R. Medeiros, and J. B. Calixto
Role of the Macrophage Inflammatory Protein-1{alpha}/CC Chemokine Receptor 5 Signaling Pathway in the Neuroinflammatory Response and Cognitive Deficits Induced by {beta}-Amyloid Peptide
Am. J. Pathol.,
October 1, 2009;
175(4):
1586 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Gorlovoy, S. Larionov, T. T. H. Pham, and H. Neumann
Accumulation of tau induced in neurites by microglial proinflammatory mediators
FASEB J,
August 1, 2009;
23(8):
2502 - 2513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cheret, A. Gervais, A. Lelli, C. Colin, L. Amar, P. Ravassard, J. Mallet, A. Cumano, K.-H. Krause, and M. Mallat
Neurotoxic Activation of Microglia Is Promoted by a Nox1-Dependent NADPH Oxidase
J. Neurosci.,
November 12, 2008;
28(46):
12039 - 12051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jimenez, D. Baglietto-Vargas, C. Caballero, I. Moreno-Gonzalez, M. Torres, R. Sanchez-Varo, D. Ruano, M. Vizuete, A. Gutierrez, and J. Vitorica
Inflammatory Response in the Hippocampus of PS1M146L/APP751SL Mouse Model of Alzheimer's Disease: Age-Dependent Switch in the Microglial Phenotype from Alternative to Classic
J. Neurosci.,
November 5, 2008;
28(45):
11650 - 11661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. M. Quintao, G. F. Passos, R. Medeiros, A. F. Paszcuk, F. L. Motta, J. B. Pesquero, M. M. Campos, and J. B. Calixto
Neuropathic Pain-Like Behavior after Brachial Plexus Avulsion in Mice: The Relevance of Kinin B1 and B2 Receptors
J. Neurosci.,
March 12, 2008;
28(11):
2856 - 2863.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
Abstract
Introduction
Compound via MeSH
